



24 June 2022
EMA/210541/2022

Agenda - Understanding the pathophysiology of thrombosis with thrombocytopenia syndrome (TTS) and discussing next steps in research

27 June 2022 13:00 – 18:30 CET

Time	Topic	Speakers
13:00 – 13:05	Welcome and adoption of agenda	Marco Cavaleri (EMA)
Session 1. Pharmacoepidemiology: Population-based studies of vaccine induced TTS Chair: Jean-Michel Dogné and Ulla Wändel Liminga		
13:05 – 13:20	Thrombosis with thrombocytopenia: background rates, historical comparisons, and cohort studies	Daniel Prieto-Alhambra (University of Oxford & Erasmus MC University Rotterdam)
13:20 – 13:35	Thromboembolic- and thrombocytopenic safety of SARS-CoV-2 vaccination in the Nordic countries: three observational approaches	Anders Peter Hviid (Statens Serum Institut & University of Copenhagen)
13:35 – 13:50	The WHO Interim Emergency Guideline on detecting and managing TTS: proposed updates	Rita Helfand (WHO GACVS) David Garcia Azorin (Hospital Clínico Universitario de Valladolid)
13:50 – 14:05	Janssen epidemiology activities to characterize the risk of TTS	Nicolas Praet (Janssen)
14:05 – 14:20	TTS - insights from epidemiology and pharmacovigilance	Nadia Foskett (AstraZeneca)
14:20 – 14:45	Discussion	all

Session 2. Clinical characterization of TTS **Chair: Jean-Michel Dogné and Ulla Wändel Liminga**

14:45 – 15:00	Clinical features of VITT	Sue Pavord (University of Oxford)
15:00 – 15:15	Anti-PF4 antibodies in TTS/VITT	Andreas Greinacher (Universitätsmedizin Greifswald)



Session 2. Clinical characterization of TTS		
Chair: Jean-Michel Dogné and Ulla Wändel Liminga		
15:15 – 15:30	An update on TTS in Australia: clinical + laboratory features and research plans	Nigel Crawford (Murdoch Childrens Research Institute), Huyen Tran (Monash University)
15:30 – 15:45	VITT: A pan-vaccine reaction in need for sensitive and specific diagnosis?	Anand Padmanabhan (Mayo Clinic)
15:45 – 16:10	Discussion	all

Break (15')

Session 3. Understanding the biological mechanisms and impact of vaccine composition on TTS		
Chair: Marco Cavaleri		
16:25 - 16:40	Understanding the mechanism of TTS – work sponsored by AstraZeneca	Taylor Cohen (AstraZeneca)
16:40 – 16:55	Janssen perspective on clinical and nonclinical aspects of TTS MoA	Kerstin Luhn (Janssen)
16:55 – 17:10	Structural Biology Enabled Identification of PF4 In Adenoviral Vaccine Associated TTS	Mitesh Borad (Mayo Clinic) Alexander Baker (Cardiff University)
17:10 – 17:25	Disease mechanisms in Vaccine-Induced Immune Thrombotic Thrombocytopenia	Ishac Nazy (McMaster University)
17:25 - 17:40	Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine	Stefan Kochanek (University of Ulm)
17:40 – 18:05	Discussion	all

Session 4. Agreement on research agenda and future directions		
Chair: Marco Cavaleri		
18:05 – 18:30	Conclusions and next steps	Marco Cavaleri (EMA), all